Analysis Of A Cystic Fibrosis-Specific Antibiogram Before And After Fda Approval Of Elexacaftor/Tezacaftor/Ivacaftor (ETI)
The highly effective cystic fibrosis transmembrane conductance regulator (CFTR) modulator elexacaftor/tezacaftor/ivacaftor (ETI) was FDA approved in 2019. Yearly cystic fibrosis-specific antibiograms at Children’s Mercy – Kansas City were analyzed pre-ETI approval (2018-2019) and post-ETI approval (2020-2021) to evaluate differences in susceptibility to antibiotics and the prevalence of selected microorganisms.
Bohannan, Kathryn; Elson, Claire; and Beyer, Jane, "Analysis Of A Cystic Fibrosis-Specific Antibiogram Before And After Fda Approval Of Elexacaftor/Tezacaftor/Ivacaftor (ETI)" (2022). Research at Children's Mercy Month 2022. 33.